[The diagnostics of dementia using MR proton spectroscopy]
1Katedra Radiologii Uniwersytet Jagielloński Collegium Medicum, Zakład Diagnostyki Obrazowej Szpitala Uniwersyteckiego w Krakowie. aurbanik@mp.pl
Przeglad Lekarski
|August 7, 2010
Summary
Magnetic Resonance Spectroscopy (MRS) can diagnose Alzheimer's disease by detecting specific metabolite changes in the brain. These changes include altered ratios of N-acetylaspartate, choline, and myo-inositol, aiding in early detection.
Area of Science:
- Neuroimaging
- Biochemistry
- Gerontology
Background:
- Ageing brains undergo degenerative processes, with Alzheimer-type dementia being a significant concern.
- Early and accurate diagnosis of dementia subtypes is crucial for effective management.
Purpose of the Study:
- To identify determinants of brain ageing and Alzheimer-type dementia using MR proton spectroscopy (1HMRS).
- To differentiate between Alzheimer's, vascular, and mixed dementia using neuroimaging biomarkers.
Main Methods:
- 1HMRS was performed on 155 participants (controls and dementia patients).
- Spectra were analyzed qualitatively and quantitatively, calculating relative concentration ratios (RCRs) for key metabolites.
- VOIs included frontal, paraventricular, parietooccipital, and hippocampal regions.
Main Results:
- Alzheimer's patients showed increased myo-inositol/creatine (ml/Cr) RCR and decreased N-acetylaspartate/creatine (NAA/Cr) RCR.
- Characteristic spectral changes included lowered NAA and elevated ml peaks in Alzheimer's.
- Vascular dementia showed Lip and Lac peaks, while mixed dementia exhibited elevated ml peaks alongside Lip and Lac.
Conclusions:
- 1HMRS analysis of RCRs and spectral profiles can reliably diagnose Alzheimer-type dementia.
- Metabolite changes identified via 1HMRS serve as key biomarkers for differentiating dementia subtypes.
